Effectiveness of date seed on glycemia and advanced glycation end-products in type 2 diabetes: a randomized placebo-controlled trial
What this study found
Date seed powder supplementation for 8 weeks improved glycemic control and several oxidative stress and AGE-related markers versus placebo. Between-group ANCOVA P values favored date seed powder for HbA1c 0.002, insulin 0.001, HOMA-IR 0.001, HOMA-B 0.020, QUICKI 0.001, LPS 0.001, TAC 0.001, SOD 0.035, s-RAGE 0.046, MDA 0.010, and pentosidine 0.041. In the active arm, HbA1c fell from 7.77 (0.42)% to 7.46 (0.33)%, FPG from 155.86 (36.47) to 141.64 (27.68) mg/dL, and HOMA-IR from 4.64 (1.49) to 3.59 (1.08).
- Study & population
- Randomized, placebo-controlled trial in adults with type 2 diabetes mellitus recruited from a diabetes clinic in Iran.
- Intervention
- Participants in the active arm received 5 g/day date seed powder orally for 8 weeks, taken daily and added to semi-solid foods such as yogurt.
- Key limitation
- The intervention was short at 8 weeks and involved a small active arm sample, limiting precision and long-term inference.
View source
Open PDFOriginal abstract
Background Type 2 diabetes mellitus (T2DM) is a chronic medical condition affecting more than 95% of people with diabetes. Traditionally, some medicinal plants have been considered as an effective approach in management of T2DM. This trial evaluated the effects of date seed powder (DSP) on glycemia indices and oxidative stress in T2DM patients. Methods In this trail, 43 patients with T2DM were randomized to two groups: either 5 g/d of the DSP or placebo for 8 weeks. Levels of glycemic indices, lipolpolysaccharide (LPS), and soluble receptor for advanced glycation end products (s-RAGE), as well as other parameters associated with oxidative stress were assessed at baseline and after 8 weeks. Independent t-test and analysis of covariance (ANCOVA) were used for between-groups comparisons at baseline and the post-intervention phase, respectively. Results The results showed that supplementation with DSP significantly decreased HbA1c (−0.30 ± 0.48%), insulin (−1.70 ± 2.21 μU/ml), HOMA-IR (−1.05 ± 0.21), HOMA-B (−0.76 ± 21.21), lipopolysaccharide (LPS) (−3.68 ± 6.05 EU/mL), and pentosidine (118.99 ± 21.67 pg/mL) ( P < 0.05, ANCOVA adjusted for baseline and confounding factors). On the other hand, DSP supplementation significantly increased total antioxidant capacity (TAC) (0.50 ± 0.26 mmol/L), superoxide dismutase (SOD) (0.69 ± 0.32 U/ml), and s-RAGE (240.13 ± 54.25 pg/mL) compared to the placebo group. FPG, hs-CRP, GPx, CML, and uric acid had no significant within- or between-group changes. Conclusion Supplementation of DSP could be considered an effective strategy to improve glycemic control and oxidative stress in T2DM patients (Registration ID at www.irct.ir : IRCT20150205020965N10).